Artivion (NYSE:AORT) Shares Down 6.6% – What’s Next?

Shares of Artivion, Inc. (NYSE:AORT) dropped 6.6% on Wednesday . The company traded as low as $33.85 and last traded at $34.1850. Approximately 397,565 shares changed hands during trading, a decline of 2% from the average daily volume of 403,735 shares. The stock had previously closed at $36.62.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AORT. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Canaccord Genuity Group decreased their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Finally, Stifel Nicolaus set a $55.00 price objective on Artivion in a report on Thursday, March 5th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $50.47.

Artivion Stock Performance

The stock has a market cap of $1.64 billion, a PE ratio of 169.88 and a beta of 1.60. The stock has a fifty day moving average of $38.28 and a 200-day moving average of $42.00. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. On average, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity

In other Artivion news, CAO Amy Horton sold 901 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $34,039.78. Following the completion of the transaction, the chief accounting officer owned 139,088 shares in the company, valued at approximately $5,254,744.64. This represents a 0.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lance A. Berry sold 6,316 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $238,618.48. Following the completion of the sale, the executive vice president owned 210,827 shares of the company’s stock, valued at $7,965,044.06. This trade represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 133,043 shares of company stock valued at $4,977,158. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd lifted its position in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion in the 3rd quarter valued at approximately $27,000. Rockefeller Capital Management L.P. increased its position in Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC increased its position in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. Finally, USA Financial Formulas raised its stake in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.